Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altace Secret Formulation Not Expected To Be Approved Until First Half Of 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Timeline suggests King may receive FDA “approvable” letter.

You may also be interested in...



Tablet Form Of King's Altace Approved

Launch of the once mystery formulation of the ACE inhibitor is anticipated in late 2007/early 2008.

Tablet Form Of King's Altace Approved

Launch of the once mystery formulation of the ACE inhibitor is anticipated in late 2007/early 2008.

Wyeth To Relinquish Altace Marketing To King At Year-End

Under a modified promotion agreement for the ACE inhibitor, King will take over sales and marketing of ramipril effective Jan. 1.

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel